{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:09:58Z","timestamp":1785607798613,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jad.2020.12.073","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T01:47:52Z","timestamp":1608860872000},"page":"547-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Time trends in pharmacological treatment of major depressive disorder: Results from the AMSP Pharmacovigilance Program from 2001\u20132017"],"prefix":"10.1016","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-7419","authenticated-orcid":false,"given":"Johanna","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf R.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4506-9055","authenticated-orcid":false,"given":"Xueqiong","family":"Bernegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"F\u00fchrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"St\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Sieberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2020.12.073_bib0001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.eurpsy.2014.02.001","article-title":"Utilization patterns of antidepressants between 1991 and 2011 in a population-based cohort of middle-aged and elderly","volume":"29","author":"Aarts","year":"2014","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0002","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00228-014-1676-z","article-title":"Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications","volume":"70","author":"Abbing-Karahagopian","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jad.2020.12.073_bib0003","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","article-title":"Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders","volume":"25","author":"Bridler","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2020.12.073_bib0004","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","article-title":"Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014","volume":"74","author":"Bushnell","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0005","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2020.12.073_bib0006","author":"DGPPN","year":"2017"},{"issue":"Suppl 1","key":"10.1016\/j.jad.2020.12.073_bib0007","first-page":"S12","article-title":"Research methods in drug surveillance","volume":"37","author":"Engel","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0008","unstructured":"Fachinfo-Service, Fachinformationsverzeichnis Deutschland, 2020. www.fachinfo.de. Accessed on April 24th, 2020."},{"key":"10.1016\/j.jad.2020.12.073_bib0009","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2020.12.073_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/YIC.0000000000000196","article-title":"Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression","volume":"33","author":"Gobbi","year":"2018","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jad.2020.12.073_bib0011","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jad.2019.01.039","article-title":"Study of antidepressant use in 5 European settings. Could economic, sociodemographic and cultural determinants be related to their use?","volume":"249","author":"Gomez-Lumbreras","year":"2019","journal-title":"J Affect Disord"},{"issue":"Suppl 1","key":"10.1016\/j.jad.2020.12.073_bib0012","first-page":"S27","article-title":"Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study","volume":"37","author":"Grohmann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0013","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00406-013-0419-y","article-title":"Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study","volume":"264","author":"Grohmann","year":"2014","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jad.2020.12.073_bib0014","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1055\/s-2004-815505","article-title":"The AMSP Drug Safety Program: Methods and Global Results","volume":"37","author":"Grohmann","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.jad.2020.12.073_bib0015","first-page":"S16","article-title":"The AMUP study for drug surveillance in psychiatry - a summary of inpatient data","volume":"37","author":"Grohmann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0016","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1176\/appi.ps.201300510","article-title":"Consumption of antidepressants in Italy: recent trends and their significance for public health","volume":"65","author":"Gualano","year":"2014","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jad.2020.12.073_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-244X-12-153","article-title":"Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP","volume":"12","author":"Haeberle","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0018","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/JCP.0000000000000954","article-title":"Trends of Polypharmacy and Prescription Patterns of Antidepressants in Asia","volume":"38","author":"Huang","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jad.2020.12.073_bib0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imj.12315","article-title":"Twenty-year trends in benzodiazepine dispensing in the Australian population","volume":"44","author":"Islam","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jad.2020.12.073_bib0020","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.jad.2020.12.073_bib0021","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S1461145711000745","article-title":"Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program","volume":"15","author":"Konstantinidis","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2020.12.073_bib0022","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/03007995.2017.1294055","article-title":"The use of adjunctive antipsychotics to treat depression in UK primary care","volume":"33","author":"Lamy","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jad.2020.12.073_bib0023","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fpsyt.2020.00035","article-title":"National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis","volume":"11","author":"Luo","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00127-016-1306-4","article-title":"Influences on antidepressant prescribing trends in the UK: 1995-2011","volume":"52","author":"Mars","year":"2017","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"10.1016\/j.jad.2020.12.073_bib0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00228-014-1803-x","article-title":"Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study","volume":"71","author":"Noordam","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jad.2020.12.073_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214240","article-title":"Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States","volume":"14","author":"Oktora","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2020.12.073_bib0027","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/archgenpsychiatry.2009.81","article-title":"National patterns in antidepressant medication treatment","volume":"66","author":"Olfson","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0028","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s40261-013-0104-y","article-title":"Psychotropic prescription patterns among patients diagnosed with depressive disorder based on claims database in Japan","volume":"33","author":"Onishi","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jad.2020.12.073_bib0029","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.1367","article-title":"Trends in psychotropic medication use among U.S. adults","volume":"16","author":"Paulose-Ram","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jad.2020.12.073_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jad.2016.04.035","article-title":"Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012","volume":"200","author":"Poppe","year":"2016","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jad.2020.12.073_bib0031","first-page":"79","article-title":"Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015","author":"Rhee","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0032","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jad.2019.04.018","article-title":"Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders","volume":"252","author":"Rhee","year":"2019","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jad.2020.12.073_bib0033","first-page":"36","article-title":"Combined antidepressants: clinical experience","volume":"25-31","author":"Rojo","year":"2005","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jad.2020.12.073_bib0034","first-page":"9","article-title":"Evolution of the prevalence and incidence of consumption of antidepressants in a Spanish region (2002-2007)","volume":"7","author":"Serna","year":"2010","journal-title":"Ment Health Fam Med"},{"key":"10.1016\/j.jad.2020.12.073_bib0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4088\/JCP.v58n0801","article-title":"Are two antidepressant mechanisms better than one?","volume":"58","author":"Stahl","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0036","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200418130-00006","article-title":"A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions","volume":"18","author":"Sullivan","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2020.12.073_bib0037","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12889-020-08984-z","article-title":"Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015","volume":"20","author":"Torres-Bondia","year":"2020","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jad.2020.12.073_bib0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00228-012-1319-1","article-title":"A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care","volume":"69","author":"Trifir\u00f2","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jad.2020.12.073_bib0039","unstructured":"World Health Organizatio (WH0), 2017. Depression and other common mental disorders: global health estimates."},{"key":"10.1016\/j.jad.2020.12.073_bib0040","unstructured":"World Health Organization (WHO), 1992. The ICD-10 Classification of Mental and Behavioural Disorders."},{"key":"10.1016\/j.jad.2020.12.073_bib0041","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/pds.3255","article-title":"Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009","volume":"21","author":"Wu","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jad.2020.12.073_bib0042","first-page":"11","article-title":"Trends in Antidepressant Use and Expenditure in Six Major Cities in China From 2013 to 2018","author":"Yu","year":"2020","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0043","first-page":"941","article-title":"Medication use patterns, health care resource utilization, and economic burden for patients with major depressive disorder in Beijing, People's Republic of China","volume":"12","author":"Zhang","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jad.2020.12.073_bib0044","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/appy.12022","article-title":"Preliminary study of patterns of medication use for depression treatment in China","volume":"5","author":"Zhang","year":"2013","journal-title":"Asia Pac Psychiatry"},{"key":"10.1016\/j.jad.2020.12.073_bib0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00737-014-0450-7","article-title":"Time trends of antidepressant drug prescriptions in men versus women in a geographically defined US population","volume":"17","author":"Zhong","year":"2014","journal-title":"Arch Womens Ment Health"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032720331633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032720331633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:54:10Z","timestamp":1759024450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032720331633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"alternative-id":["S0165032720331633"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2020.12.073","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time trends in pharmacological treatment of major depressive disorder: Results from the AMSP Pharmacovigilance Program from 2001\u20132017","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2020.12.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}